ABVX.PA ABIVAX SA (EURONEXT) -10.97% after hours 24 Mar 2026: catalysts ahead

ABVX.PA stock plunged -10.97% in after hours trade on 24 Mar 2026, dropping to EUR 97.40 on EURONEXT in Europe after a EUR 12.00 intraday move. The decline followed a session in which volume reached 182,513 shares versus an average of 193,172, signalling heavier selling. Investors are parsing company updates and trial timelines for ABIVAX SA as biotech peers and sector flows weigh on the stock. We break down the drivers, technicals, the Meyka AI grade and model forecasts to show what matters next for traders and longer-term holders.

ABVX.PA stock: price action and session drivers

ABVX.PA opened at EUR 101.80 and hit a day low of EUR 94.50 before settling at EUR 97.40 in after hours. The one-day change shows a EUR -12.00 move, equal to -10.97%, with year range between EUR 4.51 and EUR 132.00. Market attention centres on recent clinical updates and liquidity flows in the European biotech sector, which amplified the down move.

Earnings, valuation and fundamentals

ABIVAX SA reports negative earnings with EPS -4.44 and a trailing P/E of -22.79, reflecting loss-making operations typical for clinical-stage biotech. Market cap stands at EUR 8,011,740,880.00 and the company shows a Price/Sales ratio of 1,330.19, highlighting stretched valuation versus revenue. Operating cash flow per share is EUR -2.16 and the current ratio is 0.77, signalling tight near-term liquidity for the drug developer.

Technical picture and short-term signals

Technicals show momentum cooling: RSI at 47.39 and MACD histogram 0.65, with Bollinger Bands at EUR 111.94 / 102.19 / 92.43 (upper/mid/lower). Average 50-day price is EUR 102.32 and average 200-day price is EUR 77.40, so price sits below the 50-day but above the 200-day. Volume spike and an MFI of 82.56 suggest short-term selling pressure and local overbought-to-correction dynamics.

Meyka AI rates ABVX.PA and models forecasts

Meyka AI rates ABVX.PA with a score out of 100: 74.33 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly target of EUR 100.11 and a yearly target of EUR 51.19; the monthly view implies a 2.72% upside from EUR 97.40, while the yearly projection implies -47.43% downside. Forecasts are model-based projections and not guarantees.

Risks, catalysts and sector context

Key risks include clinical trial readouts, burn rate given negative free cash flow per share EUR -2.17, and sector volatility in Healthcare/Biotechnology where peers drive sentiment. Catalysts are Phase IIb/IIa results for ABX464 and programme updates for ABX196. The Healthcare sector average P/E near 29.19 provides context: ABIVAX trades atypically high on forward expectations rather than current profitability.

Trading outlook and strategy for after hours movers

Short-term traders should watch liquidity and order book depth on EURONEXT and ADR venues, given shares outstanding 79,167,400 and average volume 193,172. A conservative intraday target range is EUR 94.50–EUR 103.60; a tactical stop below EUR 92.40 (lower Bollinger band) can limit downside. Long-term investors must weigh trial milestones against stretched valuation and negative cash flows.

Final Thoughts

ABVX.PA stock registered a sharp after hours decline to EUR 97.40 on 24 Mar 2026, driven by heavier trading and sector pressure. Fundamentals show negative EPS -4.44 and significant cash burn per share EUR -2.17, while valuation metrics such as Price/Sales 1,330.19 flag that expectations are priced for successful clinical outcomes. Meyka AI rates the stock 74.33 (B+), Suggestion: BUY, but the model projects divergent horizons: monthly EUR 100.11 (implied 2.72% upside) and yearly EUR 51.19 (implied -47.43% downside). That split highlights a binary outcome risk tied to clinical readouts and financing events. Traders should prioritise event risk and trade size; longer-term investors must balance trial potential against the company’s negative cash flow and elevated valuation. For the latest price moves and institutional flows check CNBC and historical data at Investing.com. Meyka AI provides this data as an AI-powered market analysis platform; grades and forecasts are model-driven and not investment guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.